These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34247191)

  • 1. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
    Clements ME; Holtslander L; Edwards C; Todd V; Dooyema SDR; Bullock K; Bergdorf K; Zahnow CA; Connolly RM; Johnson RW
    Oncogene; 2021 Aug; 40(34):5314-5326. PubMed ID: 34247191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
    Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
    Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 4. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.
    Chen D; Sun Y; Wei Y; Zhang P; Rezaeian AH; Teruya-Feldstein J; Gupta S; Liang H; Lin HK; Hung MC; Ma L
    Nat Med; 2012 Oct; 18(10):1511-7. PubMed ID: 23001183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
    Li M; Viswanadhapalli S; Santhamma B; Pratap UP; Luo Y; Liu J; Altwegg KA; Tang W; Liu Z; Li X; Ebrahimi B; Yan H; Zou Y; Konda S; Sareddy GR; Xu Z; Chen Y; Rao MK; Brenner AJ; Kaklamani VG; Tekmal RR; Ahmed G; Raj GV; Nickisch KJ; Nair HB; Vadlamudi RK
    Commun Biol; 2021 Oct; 4(1):1235. PubMed ID: 34716410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer.
    Edwards CM; Clements ME; Vecchi LA; Johnson JA; Johnson RW
    J Bone Oncol; 2021 Dec; 31():100407. PubMed ID: 34934614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
    Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
    Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
    Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
    Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer.
    Wu HX; Cheng X; Jing XQ; Ji XP; Chen XZ; Zhang YQ; He YG; Liu K; Ye F; Sun HX; Gao HJ; Song ZJ; Wu H; Zhang XJ; Zhang T; Zhao R
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2769-2784. PubMed ID: 29751081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
    Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
    Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
    Zhang T; Chen Y; Li J; Yang F; Wu H; Dai F; Hu M; Lu X; Peng Y; Liu M; Zhao Y; Yi Z
    Neoplasia; 2014 Aug; 16(8):665-77. PubMed ID: 25220594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness.
    Streitfeld WS; Dalton AC; Howley BV; Howe PH
    Cancer Biol Ther; 2023 Dec; 24(1):2271638. PubMed ID: 37927213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
    Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
    Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
    Li J; Zhang T; Yang F; He Y; Dai F; Gao D; Chen Y; Liu M; Yi Z
    Br J Pharmacol; 2015 Aug; 172(15):3817-30. PubMed ID: 25884486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
    Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
    Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.